RIOUX PATRICE sold $111 of MNPR
RIOUX PATRICE sold 1 shares of Monopar Therapeutics (MNPR) at $111.26 on 2026-08-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is too small to affect market perception of Monopar Therapeutics.
Market read
Routine insider sale with negligible market impact.
What to watch
The 10b5-1 plan indicates pre‑arranged execution, reducing the likelihood of insider sentiment.
Background
Form 4 filings disclose insider transactions; they are primary sources for insider activity.
Ticker impact
Insider Patrice Rioux sold 1 share at $111.26 via a 10b5-1 plan, reducing holdings to 5,065 shares.
No material price impact expected.
The transaction size ($111) is trivial and disclosed via a Form 4, which is a routine insider sale.
Market effects
None; the biotech sector is unaffected by a micro‑sale.
None; the filing is U.S.‑focused and does not affect regional markets.
None
Counterpoint
If the insider were a key executive, even a tiny sale could signal concerns, but here the holder is a minor insider.
Key entities
- CompanyMonopar Therapeutics
Biotech firm listed on NASDAQ under ticker MNPR.
- InsiderPatrice Rioux
Reporter of the Form 4 transaction.
